NCT01320020View on ClinicalTrials.gov

A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Epithelial Cancer Patients
Interventions
DRUG

catumaxomab

Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose

Trial Locations (3)

1100

Prof. Christian Dittrich, Vienna

2100

Dr. Morten Soerensen, Copenhagen

08035

Dr. Josep Tabernero, Barcelona

Sponsors

Lead Sponsor

Neovii Biotech
All Listed Sponsors
lead

Neovii Biotech

INDUSTRY